David Miyamoto, MD, PhD and his team published a new method to detect and characterize circulating tumor cells in the blood more accurately with important implications for treatment of prostate cancer
Departments, Centers, & Programs:
Clark Center for Radiation Oncology
100 Blossom Street
Boston, MA 02114-2606
- MD, PhD, Harvard Medical School
- Residency, Brigham and Women's Hospital
American Board Certifications
- Radiation Oncology, American Board of Radiology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
The Miyamoto laboratory focuses on the discovery and development of novel biomarkers to guide the personalized treatment of patients with prostate cancer and bladder cancer. We focus on two general classes of biomarkers, namely those based on the molecular profiles of tumor biopsies, and those based on circulating tumors cells (CTCs) in the blood that can be sampled non-invasively and repeatedly. By analyzing these patient-derived specimens, we have identified new molecular predictors of response to therapy and potential mechanisms of treatment resistance. Our overall aim is to develop tools for “real-time precision medicine” to probe the molecular signatures of cancers as they evolve over time, and to guide the precise and rational selection of appropriate therapies for each individual patient with cancer.
- May | 21 | 2018
Drs. Henning Willers and David Miyamoto were recognized with a $150,000 grant to support their research proposal on investigating mechanisms of DNA repair after proton radiation.